Clinical Trials › NCT07221565
Enrolling by InvitationPhase 1
Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting
Sponsored by Truway Health, Inc.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 120
Target enrollment
1
U.S. states
Oct 2025
Start date
Oct 2034
Expected completion
Interventions / Treatments
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)Sham Resonance Device (Inactive Control)Low-Dose Naltrexone (LDN)
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
New York1 site
New York
MS centers in New York
Compare treatment centers near a trial site by center type, providers and trials.
View New York centersMore Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.